[news] December 14th Beijing reporting network (Medical Network) on December 8th, Conba announcement, held by the transfer of Zhencheng medicine 57.25% stake to 345 million yuan, the transferee Zhejiang Bookcom pharmaceutical investment Co., the actual controller is still the chairman Hu Jiqiang Conba beaucamp. It is reported that Zhencheng medicine is two times to 500 million yuan Conba merger to the pharmaceutical business assets, announced that this release will bring 40 million yuan of investment losses of kangenbei.

Jane Cheng medicine is China's first access to pharmaceutical distribution B2B Internet drug trading service qualification of enterprises, the company formerly known as Hangzhou Zhen Cheng Pharmaceutical Co., Ltd., founded in February 9, 2002. Originally a local pharmaceutical distribution company in Zhejiang, in 2006 after the intervention of e-commerce, the work of the pharmaceutical wholesale moved to the internet.

Jane Cheng medicine business model mainly through e-commerce to carry out drugs, medical equipment, such as wholesale, distribution and other services. The company has a medical B2B e-commerce platform -- "medicine online", for the second, third medical terminal and pharmaceutical distribution companies to provide medicines, medical equipment, health food and other medical Internet distribution services; information sharing, data analysis, network marketing, financial services, online training, software and technology value-added services for pharmaceutical distribution the channel downstream users, information technology to enhance the level of the whole industry chain; through the establishment of the "E road" cooperation with banks and other financial institutions, to carry out the supply chain financial value-added services; through the combination of 5 vanguard "and" Yunlian thousand business "and other Internet virtual integration, improve the efficiency of pharmaceutical distribution, pharmaceutical business model innovation. In addition, the regulatory authorities to provide online real-time monitoring of the regulatory channels and interfaces to ensure drug safety.

"The 2014 Conba Zhejiang Zhencheng medicine online Limited by Share Ltd 30.81% shares announcement" shows that mergers and acquisitions Zhencheng medicine is an important step in the implementation of the exploration and Conba pharmaceutical e-commerce marketing, internal marketing is conducive to accelerate the integration of resources, play the advantages of Conba pharmaceutical resources, enhance the company's overall profitability.

But since the second half of 2015 and 2016, subject to the impact of multiple events, the relevant departments of the state has greatly strengthened the supervision of the relevant areas of the use of the Internet and the internet. August 2016, the State Food and drug administration were notified Hebei Province, Shanghai City, Guangdong province food and drug administration, the end of the Internet third party platform for drug online retail pilot work.

And continue to strengthen the situation of drug safety supervision, the relevant departments of the country is expected to release online prescription drug sales policy will be difficult to introduce in the short term. At the same time, health care reform measures to reduce the circulation of medicines to be implemented in the pharmaceutical sales two ticket system is a pilot and rapid development of the policy.

These policy trends and changes in the market environment, the main business of the main pharmaceutical business B2B business and future development has brought greater uncertainty.

In addition, Zhen Cheng pharmaceutical company based on the use of electronic business platform "5 drugs" and "Yunlian thousand business" network virtual mode to further expand the business to face greater difficulties, and part of the loss of customers, business development began to suffer more serious adverse effects and impact. In addition, Jane Cheng pharmaceutical company's large and medium-sized hospital terminal market coverage has not been improved, and the adverse impact of the policy is expected to continue.

These factors led directly to Conba hope through Zhencheng medicine to strengthen the B2B pathway, through the combination of 5 vanguard mode B2C platform built to link consumer oriented products and branded products through online and offline channels, expand sales space desire is difficult to achieve.

Announcement shows that 2015 annual Zhen Cheng pharmaceutical company has not completed the expected operating results, net profit of 27 million 490 thousand yuan, accounting for 51.92% of the number of expected in 2016; the performance continued to decline, from 1 to 10, the loss amounted to 16 million 970 thousand yuan.